ESTRO 2024 - Abstract Book

S2356

Clinical - Urology

ESTRO 2024

younger participants. With a suggestion of lower QOL in the radiotherapy group, index score of “health today” median 0.82 (IQR: 0.84 to 1.00) in the surgical group and 0.87 (IQR: 0.82 to 0.90) in the radiotherapy group. However, there was very little difference with regards to pain, discomfort, anxiety or depression. This was consistent with clinician graded symptoms (CTCAE) across the two groups assessing urinary incontinence and frequency, faecal incontinence, diarrhoea and fatigue. The baseline assessment FOR did not show any difference in the patients to be treated with either surgery or radiotherapy, a third of the participants feel they cannot plan for the future due to the unpredictably of the illness, more than 13% worry that the cancer will relapse within the next 5 years and the fear of the cancer coming back gets in the way of enjoying life in more than 12% of the participants.

Conclusion:

The baseline data collected for the Q-ABC study represents the most complete prospective comparison between patients treated with either surgery or radiotherapy for MIBC. As expected, consistent with other observational data, the radiotherapy cohort were older and had more comorbidity than the surgical cohort, despite being suitable for either treatment. There was no significant difference in prevalence of bladder symptoms to suggest that this was influencing treatment modality. The fact that the groups are well balanced with regards to baseline QOL and symptoms is an excellent platform to assess longer term QOL to help clinicians and patients alike in guidance and decision making in the management of MIBC. QOL and health economic data will be available in 2025.

Keywords: bladder cancer, quality of life

References: